Screening Libraries

Loureirin A

Cat. No.: HY-N1505 CAS No.: 119425-89-7 $C_{17}H_{18}O_4$ Molecular Formula: Molecular Weight: 286.32 Target: Akt

Pathway: PI3K/Akt/mTOR

Storage: Powder -20°C 3 years

 $4^{\circ}C$ 2 years

In solvent -80°C 2 years

> -20°C 1 year

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: \geq 86.6 mg/mL (302.46 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.4926 mL	17.4630 mL	34.9260 mL
	5 mM	0.6985 mL	3.4926 mL	6.9852 mL
	10 mM	0.3493 mL	1.7463 mL	3.4926 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (7.26 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (7.26 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (7.26 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Loureirin A is a flavonoid extracted from Dragon's Blood, can inhibit Akt phosphorylation, and has antiplatelet activity.
IC ₅₀ & Target	$Akt^{[1]}$
In Vitro	Loureirin A (50 μM, 100 μM) inhibits collagen-induced platelet ATP secretion and thrombin-stimulated P-selectin expression in a dose-dependent manner. Loureirin A also significantly impairs platelet spreading on immobilized fibrinogen. Loureirin A

almost completely eliminates collagen-induced Akt phosphorylation at Ser473 at the dose of 100 μ M, and has an additive inhibitory effect with the phosphoinositide 3-kinase (PI3K) inhibitor Ly294002 on collage-induced Akt phosphorylation in platelets at 50 μ M^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Biomed Pharmacother. 2020 Sep;129:110369.
- Int Immunopharmacol. 2020 Jan;78:105953.
- Eur J Immunol. 2020 Jun;50(6):795-808.
- Orthop Surg. 2023 Apr 14.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Hao HZ, et al. Antiplatelet activity of loureirin A by attenuating Akt phosphorylation: In vitro studies. Eur J Pharmacol. 2015 Jan 5;746:63-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com